Methadone and Buprenorphine Analgesia in Older Patients

Chapter
First Online:

Abstract

Persistent pain is a common problem in older adults, with prevalence reported in epidemiological studies varying between 20 and 80 %, both in community-dwelling and institutionalized older adults [1]. Persistent pain diminishes the quality of life of older adults in many ways, due to its impact on functional autonomy, mood, sleep, and social interactions.

Keywords

Persistent Pain Analgesic Efficacy Lipophilic Drug Prescribe Opioid Conditioning Pain Modulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Gibson SJ, Lussier D. Prevalence and relevance of pain in older persons. Pain Med. 2012;13 (Suppl 2):S23–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Hwang U, Richardson LD, Sonuyi TO, Morrison RS. The effect of emergency department crowding on the management of pain in older adults with hip fracture. J Am Geriatr Soc. 2006;54:270–5.CrossRefGoogle Scholar
  3. 3.
    Auret K, Schug SA. Underutilisation of opioids in elderly patients with chronic pain: approaches to correcting the problem. Drugs Aging. 2005;22:641–54.PubMedCrossRefGoogle Scholar
  4. 4.
    AGS Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57:1331–46.CrossRefGoogle Scholar
  5. 5.
    Pergolizzi J, Böger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8:287–313.PubMedCrossRefGoogle Scholar
  6. 6.
    Gloth FM. Pain management in older adults: prevention and treatment. J Am Geriatr Soc. 2001;49:188–99.PubMedCrossRefGoogle Scholar
  7. 7.
    Davis MP, Srivastava M. Demographics, assessment and management of pain in the elderly. Drugs Aging. 2003;20:23–57.PubMedCrossRefGoogle Scholar
  8. 8.
    Kahan M, Wilson L, Mailis-Gagnon A, Srivastava A. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 2: special populations. Can Fam Physician. 2011;57:1269–76.PubMedGoogle Scholar
  9. 9.
    Hammerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly: clinical implications. Clin Pharmacokinet. 1998;35:49–64.PubMedCrossRefGoogle Scholar
  10. 10.
    Shi S, Mörike K, Klotz U. The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol. 2008;64:183–99.PubMedCrossRefGoogle Scholar
  11. 11.
    Tumer N, Scarpace PJ, Lowenthal DT. Geriatric pharmacology: basic and clinical considerations. Annu Rev Pharmacol Toxicol. 1992;32:271–302.PubMedCrossRefGoogle Scholar
  12. 12.
    Montamat SC, Cusack BJ, Vestal RE. Management of drug therapy in the elderly. N Engl J Med. 1989;321:303–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Lussier D, Pickering G. Pharmacological considerations in older patients. In: Beaulieu P, Lussier D, Porreca F, Dickenson AH, editors. Pharmacology of pain. Seattle: IASP Press; 2010. p. 547–65.Google Scholar
  14. 14.
    Kinirons MT, Crome P. Clinical pharmacokinetics considerations in the elderly: an update. Clin Pharmacokinet. 1997;33:302–12.PubMedCrossRefGoogle Scholar
  15. 15.
    Paolisso G, Gambardella A, Balbi V, Ammendola S, D’Amore A, Varrichio M. Body composition, body fat distribution, and resting metabolic rate in healthy centenarians. Am J Clin Nutr. 1995;62:746–50.PubMedGoogle Scholar
  16. 16.
    Grandison MK, Boudinot FD. Age-related changes in protein binding of drugs: implications for therapy. Clin Pharmacokinet. 2000;38:271–90.PubMedCrossRefGoogle Scholar
  17. 17.
    Butler JM, Begg EJ. Free drug metabolic clearance in elderly people. Clin Pharmacokinet. 2008;47:297–321.PubMedCrossRefGoogle Scholar
  18. 18.
    Schmucker DL. Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging. 2001;18:837–51.PubMedCrossRefGoogle Scholar
  19. 19.
    Mallet L. Age-related changes in renal function and clinical implications for drug therapy. J Geriatr Drug Ther. 1991;5:5–29.Google Scholar
  20. 20.
    Kaiko RF. Age and morphine analgesia in cancer patients with postoperative pain. Clin Pharmacol Ther. 1980;28:823–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Cepeda MS, Farrar JT, Baumgaten M, Boston R, Carr DB, Strom BL. Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther. 2003;74:102–12.PubMedCrossRefGoogle Scholar
  22. 22.
    Aubrun F, Salvi N, Coriat P, Riou B. Sex- and age-related differences in morphine requirements for postoperative pain relief. Anesthesiology. 2005;103:156–60.PubMedCrossRefGoogle Scholar
  23. 23.
    Macintyre PE, Jarvis DA. Age is the best predictor of postoperative morphine requirements. Pain. 1996;64:357–64.PubMedCrossRefGoogle Scholar
  24. 24.
    Minto CF, Schnider TW, Egan TD, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentail. I. Model development. Anesthesiology. 1997; 86:10–23.PubMedCrossRefGoogle Scholar
  25. 25.
    Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamics evaluation. J Pharmacol Exp Ther. 1987;240:159–66.PubMedGoogle Scholar
  26. 26.
    Gupta DK, Avram MJ. Rational opioid dosing in the elderly: dose and dosing interval when initiating opioid therapy. Clin Pharmacol Ther. 2012;91:339–43.PubMedCrossRefGoogle Scholar
  27. 27.
    Menten J, Desmedt M, Lossignol D, Mullie A. Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: results of a compassionate-use study with special focus on elderly patients. Curr Med Res Opin. 2002;18:488–98.PubMedCrossRefGoogle Scholar
  28. 28.
    Nasar MA, McLeavy MA, Knox J. An open study of sub-lingual buprenorphine in the treatment of chronic pain in the elderly. Curr Med Res Opin. 1986;10:251–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Likar R, Vadlau EM, Breschan C, Kager I, Korak-Keiter M, Ziervogel G. Comparable ­analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age. Clin J Pain. 2008;24:536–43.PubMedCrossRefGoogle Scholar
  30. 30.
    Buckeridge D, Huang A, Hanley J, et al. Risk of injury associated with opioid use in older adults. J Am Geriatr Soc. 2010;58:1664–70.PubMedCrossRefGoogle Scholar
  31. 31.
    Ensrud KE, Blackwell T, Mangione CM, et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med. 2003;163:949–57.PubMedCrossRefGoogle Scholar
  32. 32.
    Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc. 1999;47:30–9.PubMedGoogle Scholar
  33. 33.
    Schorr RI, Griffin MR, Daugherty JR, et al. Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene. J Gerontol. 1992;47:M111–5.CrossRefGoogle Scholar
  34. 34.
    Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010;170:1968–78.PubMedCrossRefGoogle Scholar
  35. 35.
    Takkouche B, Montes-Martinez A, Gill SS, et al. Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf. 2007;30:171–84.PubMedCrossRefGoogle Scholar
  36. 36.
    Solomon DH, Rassen JA, Glynn RJ, Garneau G, Levin R, Lee J, et al. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med. 2010;170:1979–86.PubMedCrossRefGoogle Scholar
  37. 37.
    Becker WC, O’Connor PG. The safety of opioid analgesics in the elderly: new data raise new concerns. Arch Intern Med. 2010;170:1986–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Davis MP, Walsh D. Methadone for relief of cancer pain: a review of pharmacokinetics, ­pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer. 2001;9:73–83.PubMedCrossRefGoogle Scholar
  39. 39.
    Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc. 2010;85:451–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Tegeder I, Lotsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet. 1999;37:17–40.PubMedCrossRefGoogle Scholar
  41. 41.
    Novick DM, Kreek MJ, Fanizza AM, Yancovitz SR, Gelb AM, Stenger RJ. Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther. 1981;30:353–62.PubMedCrossRefGoogle Scholar
  42. 42.
    Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet. 1996;31:410–22.PubMedCrossRefGoogle Scholar
  43. 43.
    Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC. QTc interval screening in methadone treatment. Ann Intern Med. 2009;150:387–95.PubMedCrossRefGoogle Scholar
  44. 44.
    Gallagher R. Methadone: an effective, safe drug of first choice for pain management in frail older adults. Pain Med. 2009;10:319–26.PubMedCrossRefGoogle Scholar
  45. 45.
    Hanlon JT, Weiner DK. Methadone for chronic pain in older adults: blast from the past but are we ready for it to return to prime time? Pain Med. 2009;10:287–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Schofield J, Smith KJ, Mundin G, et al. Pharmacokinetics of buprenorphine 5 micrograms/hour transdermal analgesic patch when applied at four application sites in healthy elderly subjects of varying body fat composition [abstract no. PH307]. Twelfth world congress on pain, Glasgow, 17–22 Aug 2008.Google Scholar
  47. 47.
    Plosker GL. Bupenorphine 5, 10 and 20 mcg/h transdermal patch: a review of its use in the management of chronic non-malignant pain. Drugs. 2011;71:2491–509.PubMedCrossRefGoogle Scholar
  48. 48.
    Butrans (buprenorphine) transdermal system for transdermal administration: US prescribing information [online]. http://www.purduepharma.com/pi/prescription/butranspi.pdf. Accessed 20 Feb 2012.
  49. 49.
    Filitz J, Griessinger N, Sittl R, Likar R, Schüttler J, Koppert W. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain. 2006;10:743–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Dahan A. Opioid-induced respiratory effects: new data on buprenorphine. Palliat Med. 2006;20:S3–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Martucci C, Panerai AE, Sacerdote P. Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. Pain. 2004; 110:385–92.PubMedCrossRefGoogle Scholar
  52. 52.
    Pergolizzi J, Aloisi AM, Dahan A, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10:428–50.PubMedCrossRefGoogle Scholar
  53. 53.
    Dagtekin P, Gerbershagen HJ, Wagner W, Petzke F, Radbruch L, Sabatowski R. Assessing cognitive and psychomotor performance under long-term treatment with transdermal buprenorphine in chronic non-cancer patients. Anesth Analg. 2007;105:1442–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Arendt-Nielsen L, Nie H, Laursen MB, et al. Sensitization in patients with painful knee osteoarthritis. Pain. 2010;149:573–81.PubMedCrossRefGoogle Scholar
  55. 55.
    Washington LL, Gibson SJ, Helme RD. Age-related differences in the endogenous analgesic response to repeated cold water immersion in human volunteers. Pain. 2000;89:89–96.PubMedCrossRefGoogle Scholar
  56. 56.
    Arendt-Nielsen L, Andresen T, Malver LP, Oksche A, Mansikka H, Drewes A. A double-blind, placebo-controlled study on the effect of buprenorphine and fentanyl on descending pan modulation: a human experimental study. Clin J Pain. 2012;28:623–7.Google Scholar
  57. 57.
    Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice—a post-­marketing surveillance study in 13 179 patients. Curr Med Res Opin. 2005;21:1147–56.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Institut universitaire de gériatrie de MontréalUniversity of MontrealMontrealCanada
  2. 2.Division of Geriatric Medicine and Alan-Edwards Centre for Pain ResearchMcGill UniversityMontrealCanada

Personalised recommendations